Modified APOC3 siRNA Conjugate for Long-Acting Lipid Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dyslipidemia, such as statins and fibrates, are inadequate in effectively silencing the Apolipoprotein C3 (APOC3) gene expression, which is crucial for lipid metabolism and heart disease prevention.
Innovation Solution
Development of a siRNA conjugate with specific nucleotide sequences and modifications, including fluoro and methoxy modified nucleotides, designed to inhibit APOC3 gene expression, formulated into a pharmaceutical composition for targeted delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional medicines (statins, fibrates) are used to treat dyslipidemia, then lipid levels can be partially controlled, but the APOC3 gene expression cannot be effectively silenced
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of siRNA molecules through various nucleotide modifications (2'-O-methyl, phosphorothioate, fluoro modifications) to enhance stability and gene silencing efficacy. These chemical parameter changes enable the siRNA to resist degradation and effectively silence APOC3 gene expression, overcoming the limitation of conventional medicines that cannot achieve effective gene silencing.
Solution Approach 2:
The patent employs composite materials by formulating siRNA conjugates with cholesterol or other delivery molecules. This composite structure combines the gene-silencing capability of siRNA with the cell-penetrating and stability-enhancing properties of the conjugate molecules, creating a more effective treatment that can successfully deliver and maintain APOC3 gene silencing in vivo.
2Reliability
If siRNA is used to inhibit APOC3 gene expression, then gene silencing efficacy is improved, but stability and duration of action are insufficient
Solution Approach 1:
The patent applies parameter changes through extensive chemical modifications of the siRNA structure, including 2'-O-methyl modifications at specific positions, phosphorothioate backbone modifications, and fluoro modifications. These parameter changes dramatically enhance the stability of siRNA against nucleases and extend its duration of action in vivo, maintaining effective APOC3 gene suppression for extended periods after single administration.
Solution Approach 2:
The patent uses composite materials by conjugating siRNA with cholesterol or other amphipathic molecules. This composite structure protects the siRNA from degradation, enhances its pharmacokinetic properties, and extends its duration of action in the bloodstream and target tissues, enabling sustained gene silencing effects.
3Reliability
If highly modified siRNA conjugates are developed to improve stability and efficacy, then gene suppression activity increases, but device complexity and manufacturing difficulty increase
Solution Approach 1:
The patent applies local quality by implementing modifications at specific, strategically chosen positions within the siRNA sequence rather than uniform modification throughout. For example, 2'-O-methyl modifications are placed at specific nucleotide positions in the sense and antisense strands, and phosphorothioate modifications are concentrated at the ends and critical regions. This localized approach maintains gene silencing efficacy while reducing overall molecular complexity compared to full modification.
Solution Approach 2:
The patent uses parameter changes to optimize the degree and type of modifications, balancing efficacy and complexity. By carefully controlling the number and position of modifications (e.g., specific numbers of phosphorothioate linkages, particular 2'-O-methyl positions), the patent achieves effective blood lipid reduction while managing structural complexity for practical manufacturing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The siRNA conjugate exhibits high stability and significantly reduces blood lipid levels, maintaining inhibitory effects on APOC3 mRNA expression for up to 189 days, effectively treating and preventing dyslipidemia.
Implementation Method 1
Based on the mechanism of RNA interference (RNAi), small interfering RNA (siRNA) could inhibit or block the expression of any target gene of interest in a sequence-specific manner
Data Source
AI summary
Provided are an siRNA for inhibiting the expression of the apolipoprotein C3 gene, and a pharmaceutical composition and a conjugate containing the siRNA. Each nucleotide in the siRNA is, respectively and independently, a modified or unmodified nucleotide; the siRNA contains a sense strand and an anti-sense strand; the sense strand includes nucleotide sequence I; nucleotide sequence I has the same length as the nucleotide sequence as shown in SEQ ID NO: 1, and not more than three nucleotides are different; the anti-sense strand contains nucleotide sequence II; and nucleotide sequence II has the same length as the nucleotide sequence as shown in SEQ ID NO: 2, and not more than three nucleotides are different. The siRNA provided by the present disclosure and the pharmaceutical composition and the conjugate thereof can effectively treat and/or prevent dyslipidemia.